Developer docs
API playgroundTry for free, no card

Search company profiles

CTX Life Sciences

Full company profile

uuid000ee6c

Namestring
CTX Life Sciences
Legal namestring
CTX Lifesciences Pvt. Ltd.
Websiteurl
ctxls.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

CTX Life Sciences (legal entity CTX Lifesciences Pvt. Ltd.) is an India-based, privately held Active Pharmaceutical Ingredient (API) and intermediate manufacturer founded in 2004 in Surat, Gujarat, and operating as the pharmaceutical arm of the Colourtex Group (a diversified dyes, textiles and masterbatches conglomerate with $600M+ annual sales founded in 1967). The company runs a 38-acre cGMP-compliant manufacturing campus in Sachin GIDC, Surat, comprising five production blocks with a collective reactor volume exceeding 1,000 KL, supported by kilo labs, a pilot plant, advanced analytical instrumentation (UHPLC, GC-MS, XRD, ICP OES, DSC, Karl Fischer), and full environmental infrastructure (ETP, MEE, ATFD, 5,850 TR cooling, 4,250 KVA power backup). Its R&D arm is a 12,000 sq ft DSIR-approved laboratory staffed by 77+ scientists covering process and analytical development for 30+ reaction types including oxidative chlorination, catalytic reduction, enzymatic reactions, Vilsmeier Haack and asymmetric reductions.

The company's product portfolio spans 40+ commercial APIs across anti-hypertensive, anti-diabetic, anti-convulsant, anti-coagulant, anti-psychotic, diuretic, CNS and cardiovascular therapeutic categories, 20+ pharmaceutical intermediates and four APIs in development (Brivaracetam, Dabigatran Etexilate Mesylate, Edoxaban Tosylate, Mirogabalin Besylate). It serves 800+ customers in 87+ countries via direct B2B export, backed by DMF/CEP filings across US, European, Brazilian, Korean, Japanese, Canadian, Mexican and Russian health authorities, with USFDA inspections completed six times (most recently 2022) and EDQM inspections four times. In parallel, CTX offers CDMO services providing end-to-end process development, scale-up and commercial manufacturing under cGMP, leveraging vertical integration from Key Starting Materials through intermediates to finished APIs. Revenue is generated through transaction-fee API sales, CDMO contracts and intermediate/KSM supply; pricing is not publicly disclosed and customer inquiries are routed through info@ctxls.com.

Short descriptiontext

CTX Life Sciences is a Surat, India-based, privately held API and intermediate manufacturer operating a USFDA- and EU GMP-inspected facility, supplying 40+ commercial APIs and 20+ intermediates to 800+ pharmaceutical customers across 87+ countries under its parent Colourtex Group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSurat, India
HQ citystring
Surat
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
API manufacturing, pharmaceutical intermediates, contract development manufacturing, cGMP API supply, regulatory DMF filings
Industry1 code
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
API Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1API Sales
TypeTransaction Fee
Description

Sale of Active Pharmaceutical Ingredients to pharmaceutical companies worldwide with regulatory filings (DMF, CEP) across multiple markets. 40+ commercial APIs covering anti-hypertensive, anti-diabetic, anti-convulsant, anti-coagulant, anti-psychotic, diuretic segments.

ctxls.com
2Contract Development and Manufacturing (CDMO)
TypeTransaction Fee
Description

End-to-end development and manufacturing services for pharmaceutical companies including process development, optimization, scale-up and commercial production under cGMP conditions.

ctxls.com
3Intermediates and KSM Sales
TypeTransaction Fee
Description

Manufacturing and supply of pharmaceutical intermediates and Key Starting Materials to pharmaceutical companies. Backward integrated processes offering better control over quality, cost and supply consistency.

ctxls.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CTX Lifesciences is a vertically integrated pharmaceutical manufacturer that produces 40+ commercial Active Pharmaceutical Ingredients (APIs), 20+ pharmaceutical intermediates, and provides Contract Development and Manufacturing Organization (CDMO) services for global pharmaceutical companies. Manufacturing is conducted under cGMP conditions with regulatory filings (USDMF, CEP, EDMF, KDMF, ANVISA, COFEPRIS, JDMF, NMPA, MOH Russia) supporting exports to 87+ countries. Therapeutic segments covered include anti-hypertensive, anti-diabetic, anti-convulsant, anti-coagulant, anti-psychotic, and diuretic categories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successfully passed 6 USFDA inspections and 4 EDQM inspections demonstrating consistent regulatory compliance
+2 more records
Product overview1 text field

CTX Lifesciences is a vertically integrated Active Pharmaceutical Ingredient (API) and intermediate manufacturer offering a comprehensive portfolio of 40+ commercial APIs across therapeutic categories including anti-hypertensives, anti-diabetics, anti-coagulants, anti-convulsants, anti-psychotics, and diuretics. The company also develops 4 additional APIs and manufactures 20+ pharmaceutical intermediates. CTX provides Contract Development and Manufacturing Organization (CDMO) services with vertical integration from Key Starting Materials (KSM) to intermediates to finished APIs. All products are manufactured under cGMP conditions with regulatory filings including USDMF, CEP, EDMF, NMPA, KFDA, MOH Russia, ANVISA, and other international drug authorities.

Product and service3 records
1Commercial APIs
CategoryActive Pharmaceutical Ingredients
Description

A portfolio of 40+ commercial Active Pharmaceutical Ingredients (APIs) sold to pharmaceutical companies worldwide with regulatory filings (USDMF, CEP, KDMF, ANVISA, MOH Russia, COFEPRIS, JDMF, NMPA). Includes products such as Acetazolamide, Alogliptin Benzoate, Apixaban, Azilsartan Medoxomil Potassium, Dapagliflozin Propanediol Monohydrate, Empagliflozin, Linagliptin, Metoprolol Succinate, Pregabalin, Rosuvastatin Calcium, Ticagrelor, and Vildagliptin across therapeutic segments.

2Pharmaceutical Intermediates
CategoryPharmaceutical Intermediates
Description

20+ pharmaceutical intermediates including 2-Acetylamino-5-mercapto-1,3,4-thiadiazole and other specialty intermediates for APIs such as Acetazolamide, Alogliptin Benzoate, Apixaban, Azilsartan Medoxomil Potassium, Carvedilol, Celecoxib, Chlorthalidone, Dabigatran Etexilate Mesylate, Deferasirox, Eslicarbazepine Acetate, Lamotrigine, Linagliptin, Losartan Potassium, Olmesartan Medoxomil, Rosuvastatin Calcium, Saxagliptin, Sevelamer HCl, and Vildagliptin.

3Contract Development and Manufacturing Organization (CDMO) Services
CategoryContract Manufacturing Services
Description

End-to-end contract development and manufacturing services for pharmaceutical companies, including process development, optimization, scale-up and commercial production under cGMP conditions. Includes vertical integration of intermediates and Key Starting Materials (KSM), with state-of-the-art facilities and experienced team supporting project timelines, budget adherence, and attention to quality and safety.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOthers
Description

Parent company privately owned Colourtex Industries Pvt Ltd founded by Jayantibhai Jariwala in 1967, worth US$ 600 million group. Leading dyestuff manufacturer with 750+ types of dyes and performance chemicals. Provides chemical manufacturing expertise and environmental infrastructure including ETP, MEE, ATFD, power generation, and water treatment facilities. Group also has interests in Textiles and Masterbatches.

2NGOs, Self-Help Groups, Government Bodies, Social Enterprises
Strategic tierMinorTypeOthers
Description

CSR collaborations for social responsibility initiatives focusing on education, health and wellness, sanitation, environment, and sustainable holistic development in marginalized and economically disadvantaged sections of society.

ctxls.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian-based API manufacturer and CDMO with strong complex chemistry capabilities, USFDA-inspected facilities, and a comparable focus on regulated markets — a direct competitor for generic API and contract manufacturing contracts.

TypeDirect peer
Description

Vertically integrated Indian API and CDMO with KSM-to-API integration and strong regulatory filings, competing head-to-head with CTX in generic APIs and emerging CDMO opportunities.

TypeDirect peer
Description

One of India's largest generic API and finished-dose manufacturers with extensive USFDA-inspected facilities and similar therapeutic coverage (cardiovascular, anti-diabetic, CNS) — overlapping customer base and product portfolio.

TypeDirect peer
Description

Indian API manufacturer and CDMO focused on complex generics and peptide APIs, with USFDA-inspected facilities and similar product mix to CTX in cardiovascular and CNS therapeutic areas.

TypeDirect peer
Description

Indian pharmaceutical company with significant API manufacturing and CDMO services, including complex chemistry and injectable capabilities, competing for similar CDMO contracts in regulated markets.

TypeDirect peer
Description

Indian API and finished-dose manufacturer with vertically integrated paracetamol, metformin, and other high-volume API capabilities, overlapping with CTX in commodity generic APIs.

TypeDirect peer
Description

Indian API and formulation manufacturer with oncology and complex generic focus, sharing the CDMO and regulated API market with CTX.

TypeDirect peer
Description

Major Indian CDMO offering API, peptide, and sterile fill-finish services; competes with CTX for innovator pharma contract manufacturing opportunities, with a broader capability set including biologics.

TypeDirect peer
Description

Indian CDMO focused on small molecule API development and manufacturing, with strong process R&D capabilities — directly comparable in target customer (innovator pharma) and service offering.

TypeRegional player
Description

Indian API manufacturer with similar therapeutic area coverage (anti-diabetic, cardiovascular) and export focus, competing with CTX primarily in semi-regulated and emerging markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CTX Life Sciences

API Manufacturingctxls.com

CTX Life Sciences is a Surat, India-based, privately held API and intermediate manufacturer operating a USFDA- and EU GMP-inspected facility, supplying 40+ commercial APIs and 20+ intermediates to 800+ pharmaceutical customers across 87+ countries under its parent Colourtex Group.

What CTX Life Sciences does

CTX Life Sciences (legal entity CTX Lifesciences Pvt. Ltd.) is an India-based, privately held Active Pharmaceutical Ingredient (API) and intermediate manufacturer founded in 2004 in Surat, Gujarat, and operating as the pharmaceutical arm of the Colourtex Group (a diversified dyes, textiles and masterbatches conglomerate with $600M+ annual sales founded in 1967). The company runs a 38-acre cGMP-compliant manufacturing campus in Sachin GIDC, Surat, comprising five production blocks with a collective reactor volume exceeding 1,000 KL, supported by kilo labs, a pilot plant, advanced analytical instrumentation (UHPLC, GC-MS, XRD, ICP OES, DSC, Karl Fischer), and full environmental infrastructure (ETP, MEE, ATFD, 5,850 TR cooling, 4,250 KVA power backup). Its R&D arm is a 12,000 sq ft DSIR-approved laboratory staffed by 77+ scientists covering process and analytical development for 30+ reaction types including oxidative chlorination, catalytic reduction, enzymatic reactions, Vilsmeier Haack and asymmetric reductions.

The company's product portfolio spans 40+ commercial APIs across anti-hypertensive, anti-diabetic, anti-convulsant, anti-coagulant, anti-psychotic, diuretic, CNS and cardiovascular therapeutic categories, 20+ pharmaceutical intermediates and four APIs in development (Brivaracetam, Dabigatran Etexilate Mesylate, Edoxaban Tosylate, Mirogabalin Besylate). It serves 800+ customers in 87+ countries via direct B2B export, backed by DMF/CEP filings across US, European, Brazilian, Korean, Japanese, Canadian, Mexican and Russian health authorities, with USFDA inspections completed six times (most recently 2022) and EDQM inspections four times. In parallel, CTX offers CDMO services providing end-to-end process development, scale-up and commercial manufacturing under cGMP, leveraging vertical integration from Key Starting Materials through intermediates to finished APIs. Revenue is generated through transaction-fee API sales, CDMO contracts and intermediate/KSM supply; pricing is not publicly disclosed and customer inquiries are routed through info@ctxls.com.

CTX Life Sciences firmographics

Firmographics
Name
CTX Life Sciences
Legal name
CTX Lifesciences Pvt. Ltd.
Website
https://ctxls.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
251–500 employees
Short description
CTX Life Sciences is a Surat, India-based, privately held API and intermediate manufacturer operating a USFDA- and EU GMP-inspected facility, supplying 40+ commercial APIs and 20+ intermediates to 800+ pharmaceutical customers across 87+ countries under its parent Colourtex Group.
Ownership category
akta.pro rank

CTX Life Sciences industry classification

Industry
Product category
API Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • API manufacturing
  • Pharmaceutical intermediates
  • Contract development manufacturing
  • CGMP API supply
  • Regulatory DMF filings

Where CTX Life Sciences is headquartered

Location

Headquarters

HQ city
Surat
HQ country
India
HQ region
Asia

Offices2 records

Markets served

CTX Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Infrastructure, Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. API Sales: Sale of Active Pharmaceutical Ingredients to pharmaceutical companies worldwide with regulatory filings (DMF, CEP) across multiple markets. 40+ commercial APIs covering anti-hypertensive, anti-diabetic, anti-convulsant, anti-coagulant, anti-psychotic, diuretic segments.
  2. Contract Development and Manufacturing (CDMO): End-to-end development and manufacturing services for pharmaceutical companies including process development, optimization, scale-up and commercial production under cGMP conditions.
  3. Intermediates and KSM Sales: Manufacturing and supply of pharmaceutical intermediates and Key Starting Materials to pharmaceutical companies. Backward integrated processes offering better control over quality, cost and supply consistency.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

CTX Life Sciences product offering

Product offering

Core offering

CTX Lifesciences is a vertically integrated pharmaceutical manufacturer that produces 40+ commercial Active Pharmaceutical Ingredients (APIs), 20+ pharmaceutical intermediates, and provides Contract Development and Manufacturing Organization (CDMO) services for global pharmaceutical companies. Manufacturing is conducted under cGMP conditions with regulatory filings (USDMF, CEP, EDMF, KDMF, ANVISA, COFEPRIS, JDMF, NMPA, MOH Russia) supporting exports to 87+ countries. Therapeutic segments covered include anti-hypertensive, anti-diabetic, anti-convulsant, anti-coagulant, anti-psychotic, and diuretic categories.

Product overview

CTX Lifesciences is a vertically integrated Active Pharmaceutical Ingredient (API) and intermediate manufacturer offering a comprehensive portfolio of 40+ commercial APIs across therapeutic categories including anti-hypertensives, anti-diabetics, anti-coagulants, anti-convulsants, anti-psychotics, and diuretics. The company also develops 4 additional APIs and manufactures 20+ pharmaceutical intermediates. CTX provides Contract Development and Manufacturing Organization (CDMO) services with vertical integration from Key Starting Materials (KSM) to intermediates to finished APIs. All products are manufactured under cGMP conditions with regulatory filings including USDMF, CEP, EDMF, NMPA, KFDA, MOH Russia, ANVISA, and other international drug authorities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Commercial APIs A portfolio of 40+ commercial Active Pharmaceutical Ingredients (APIs) sold to pharmaceutical companies worldwide with regulatory filings (USDMF, CEP, KDMF, ANVISA, MOH Russia, COFEPRIS, JDMF, NMPA). Includes products such as Acetazolamide, Alogliptin Benzoate, Apixaban, Azilsartan Medoxomil Potassium, Dapagliflozin Propanediol Monohydrate, Empagliflozin, Linagliptin, Metoprolol Succinate, Pregabalin, Rosuvastatin Calcium, Ticagrelor, and Vildagliptin across therapeutic segments.
  • Pharmaceutical Intermediates 20+ pharmaceutical intermediates including 2-Acetylamino-5-mercapto-1,3,4-thiadiazole and other specialty intermediates for APIs such as Acetazolamide, Alogliptin Benzoate, Apixaban, Azilsartan Medoxomil Potassium, Carvedilol, Celecoxib, Chlorthalidone, Dabigatran Etexilate Mesylate, Deferasirox, Eslicarbazepine Acetate, Lamotrigine, Linagliptin, Losartan Potassium, Olmesartan Medoxomil, Rosuvastatin Calcium, Saxagliptin, Sevelamer HCl, and Vildagliptin.
  • Contract Development and Manufacturing Organization (CDMO) Services End-to-end contract development and manufacturing services for pharmaceutical companies, including process development, optimization, scale-up and commercial production under cGMP conditions. Includes vertical integration of intermediates and Key Starting Materials (KSM), with state-of-the-art facilities and experienced team supporting project timelines, budget adherence, and attention to quality and safety.

Quantifiable outcome

  • Successfully passed 6 USFDA inspections and 4 EDQM inspections demonstrating consistent regulatory compliance
  • +2 more outcomes

Companies that use CTX Life Sciences

Customer profile

Segments3 records

Ideal customer profiles2 records

CTX Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CTX Life Sciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Colourtex GroupcoreOthersParent company privately owned Colourtex Industries Pvt Ltd founded by Jayantibhai Jariwala in 1967, worth US$ 600 million group. Leading dyestuff manufacturer with 750+ types of dyes and performance chemicals. Provides chemical manufacturing expertise and environmental infrastructure including ETP, MEE, ATFD, power generation, and water treatment facilities. Group also has interests in Textiles and Masterbatches.
  • NGOs, Self-Help Groups, Government Bodies, Social EnterprisesminorOthersCSR collaborations for social responsibility initiatives focusing on education, health and wellness, sanitation, environment, and sustainable holistic development in marginalized and economically disadvantaged sections of society.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

CTX Life Sciences competitors and assessment

Company assessment

Direct peers

  • Divis Laboratories: Indian-based API manufacturer and CDMO with strong complex chemistry capabilities, USFDA-inspected facilities, and a comparable focus on regulated markets — a direct competitor for generic API and contract manufacturing contracts.
  • Laurus Labs: Vertically integrated Indian API and CDMO with KSM-to-API integration and strong regulatory filings, competing head-to-head with CTX in generic APIs and emerging CDMO opportunities.
  • Aurobindo Pharma: One of India's largest generic API and finished-dose manufacturers with extensive USFDA-inspected facilities and similar therapeutic coverage (cardiovascular, anti-diabetic, CNS) — overlapping customer base and product portfolio.
  • Neuland Laboratories: Indian API manufacturer and CDMO focused on complex generics and peptide APIs, with USFDA-inspected facilities and similar product mix to CTX in cardiovascular and CNS therapeutic areas.
  • Jubilant Pharmova: Indian pharmaceutical company with significant API manufacturing and CDMO services, including complex chemistry and injectable capabilities, competing for similar CDMO contracts in regulated markets.
  • Granules India: Indian API and finished-dose manufacturer with vertically integrated paracetamol, metformin, and other high-volume API capabilities, overlapping with CTX in commodity generic APIs.
  • Shilpa Medicare: Indian API and formulation manufacturer with oncology and complex generic focus, sharing the CDMO and regulated API market with CTX.
  • Piramal Pharma Solutions: Major Indian CDMO offering API, peptide, and sterile fill-finish services; competes with CTX for innovator pharma contract manufacturing opportunities, with a broader capability set including biologics.
  • Sai Life Sciences: Indian CDMO focused on small molecule API development and manufacturing, with strong process R&D capabilities — directly comparable in target customer (innovator pharma) and service offering.

Regional players

  • Aarti Drugs: Indian API manufacturer with similar therapeutic area coverage (anti-diabetic, cardiovascular) and export focus, competing with CTX primarily in semi-regulated and emerging markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

CTX Life Sciences social profiles

Digital presence

CTX Life Sciences compliance and trust

Trust signal

Compliance12 records

CTX Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CTX Life Sciences leadership team

Management profile

Number of profiles

Profiles1 record

CTX Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CTX Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CTX Life Sciences

What does CTX Life Sciences do?

CTX Lifesciences is a vertically integrated pharmaceutical manufacturer that produces 40+ commercial Active Pharmaceutical Ingredients (APIs), 20+ pharmaceutical intermediates, and provides Contract Development and Manufacturing Organization (CDMO) services for global pharmaceutical companies. Manufacturing is conducted under cGMP conditions with regulatory filings (USDMF, CEP, EDMF, KDMF, ANVISA, COFEPRIS, JDMF, NMPA, MOH Russia) supporting exports to 87+ countries. Therapeutic segments covered include anti-hypertensive, anti-diabetic, anti-convulsant, anti-coagulant, anti-psychotic, and diuretic categories.

Is CTX Life Sciences a public or private company?

CTX Life Sciences is a private company. It is classified as corporate owned and is currently operating.

When was CTX Life Sciences founded?

CTX Life Sciences was founded in 2004. It employs 251 to 500 people.

Where is CTX Life Sciences based?

CTX Life Sciences is headquartered in Surat, India, in the Asia region.

How does CTX Life Sciences make money?

Three revenue lines are on record. API Sales are the primary driver. The others are contract Development and Manufacturing (CDMO) and intermediates and KSM Sales.

Who are CTX Life Sciences's main competitors?

Direct peers on record are Divis Laboratories, Laurus Labs, Aurobindo Pharma, Neuland Laboratories, Jubilant Pharmova, Granules India, Shilpa Medicare, Piramal Pharma Solutions and Sai Life Sciences. Aarti Drugs is listed as a regional player.

Does CTX Life Sciences have an API?

No public API is recorded for CTX Life Sciences.

What industry is CTX Life Sciences in?

CTX Life Sciences's product category is API Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals